Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,

Slides:



Advertisements
Similar presentations
DrMohammadSadrkabir Editor:. FREQUENCY OF ELEVATED HEPATOCELLULAR CARCINOMA (HCC) BIOMARKERS IN PATIENTS WITH ADVANCED HEPATITIS C The American Journal.
Advertisements

Outline Biomarkers for early detection of HCC - Currently so called HCC biomarker - AFP - Our proposed HCC biomarkers - PIVKAII - GGTII - Detection of.
High Intensity Focused Ultrasound (HIFU) for Liver Tumour Dr Dai Wing Chiu Queen Mary Hospital.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
Doç.Dr. Jale Çoban Klinik Biyokimya Uzmanı
Protein GP73 (GOLGI PROTEIN 73) A NEW NON-INVASIVE BIOMARKER FOR ASSESSING LIVER FIBROSIS AND RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA N.K. Gatselis,
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Eleni Galani Medical Oncologist
HEPATOCELLULAR CARCINOMA Monton. HCC in Thailand Most common cancer in Thai male Incidence 5 x 100,000 / year Male : female = 3-8:1 Age > 40 yr.
Guzman, Alexander Joseph Hipolito, April Lorraine
Surveillance for HCC. Surveillance in cancer Definition: Repeated application of a test over time with the aim of reducing disease-specific mortality.
Basic statistics 11/09/13.
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US Radiology 2015; 275:
FT in prognostic of HBV FibroTest: predictive value in HBV.
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
وما أوتيتم من العلم إلا قليلاً. Prepared by: Abdo A Elfiky.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Use of Single Data Source Can Significantly Underestimate Hepatitis C Mortality Rates Slideset on: Wu C, Chang HG, McNutt LA, Smith PF. Estimating the.
HCC Guidelines
Serum Levels of Glycosaminoglycans (GAGs) and Insulin Like Growth Factor-1 (IGF-1) as New Diagnostic Markers for Hepatocellular Carcinoma. Ahmad S. Ibrahim*,
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.
Evaluation of risk for esophageal varices by transient elastometry in patients with HIV and HCV infection and liver cirrhosis M.K. Mausolf 1, M. Berger.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Validation of Biomarkers for Hepatocellular Carcinoma Jorge A. Marrero, M.D., M.S.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Thomas Sersté1,2, Vincent Barrau3, Violaine Ozenne1, Marie Pierre Vullierme3, Pierre Bedossa5,6, Olivier Farges4, Dominique-Charles Valla1,6, Valérie Vilgrain3,6,
Coffee and Tea Intake Appears Protective Against Chronic Liver Disease Slideset on: Ruhl CE, Everhart JE. Coffee and tea consumption are associated with.
Identification of Potential Risk Factors for Mother-to- Infant HCV Transmission Slideset on: Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal.
Raised Plasma Homocysteine Concentration in Pregnancy as a Predictor of Preeclampsia Pandya B 1,2, Awan N 1, Shah S 2, Pande R 3, Prasad V 1, Myers M 3,
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.
HEPATOLOGY, Vol. 61, No. 6, Introduction At least 1 / 3 of liver cirrhosis (LC) Chronic hepatitis B (CHB) Significant proportion of CHB progress.
TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
SURGICAL ONCOLOGY AND TUMOR MARKERS
Dr. Mohammed Omar Khalifa
Ovarian tumor markers Associate Professor Fariba Behnamfar
W Tormey6, CJ Thompson1, D Smith1, A Agha1.
Immunoscore Prognostic in Colon Cancer
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
39 DEVELOPED HCC by EASL criteria
Performance Comparison of CA125 and the Combination of the Other Serum Biomarkers for the Early Detection of the Ovarian Cancer Hye-Jeong Song1,3,
Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.
Cell Physiol Biochem 2016;40: DOI: /
Presented By: Sally Saad Mandour Esawy
Additional file 2 Total HCC cases N=39
A New Paradigm for Early Diagnosis and Surveillance
MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /
AFP > 9000 without demonstrable HCC
Figure 2 A stage-based approach to the treatment of NAFLD
Volume 137, Issue 1, Pages (July 2009)
HEPATOCELLULAR CARCINOMA (HCC) at
Evaluation of the Patient With HCV Infection
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
VIETNAM MILITARY MEDICAL UNIVERSITY
Volume 154, Issue 6, Pages e1 (May 2018)
Mezale D*1, Strumfa I1, Balodis D1, Vanags A2, Rumba R2
Hepatocellular Carcinoma in Patients with
Josep M. Llovet  Clinical Gastroenterology and Hepatology 
ULTRASOUND NEWS
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Markov model of HCV–HCC disease process.
Presentation transcript:

Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43:

clinicaloptions.com/hep Golgi Protein 73 as Serum Marker for HCC Background  Incidence of hepatocellular carcinoma (HCC) rising in US  Current diagnostic tools inadequate –Alpha-fetoprotein (AFP) in serum; low positive predictive value –Liver ultrasound; accuracy dependent on skills of technician  Golgi protein (GP73) upregulated in patients with liver disease and in animal models of HCC  Current study evaluated sensitivity and specificity of serum GP73 levels for diagnosing HCC Marrero J, et al. J Hepatol. 2005;43:

clinicaloptions.com/hep Golgi Protein 73 as Serum Marker for HCC Study Design  Cases and controls recruited from University of Michigan,  GP73 levels in sera from patients measured with Western blot –Triplicate determinations were performed for each serum sample –Interassay variability: 8% –Intra-assay variability: 10%  HCC case patients –HCC diagnosed by histopathology (preferred) or 2 imaging method  Control group 1 –No history of liver disease –< 40 g alcohol/week –No risk factors for hepatitis  Control group 2 –Cirrhosis patients –Matched to HCC patients by age, sex, race Marrero J, et al. J Hepatol. 2005;43:

clinicaloptions.com/hep Golgi Protein 73 as Serum Marker for HCC Study Results Serum Marker, Median Relative Units (Range) No Liver DiseaseCirrhosisEarly HCC*All HCCP Value † GP ( ) 4.6 ( ) 12.8 (1-50) 13.2 (1-53) <.0001 AFP 2.5 ( ) 5.9 ( ) 10.9 ( ,000) 15.6 ( ,000) <.0001  GP73 detected in serum of all patients –Levels significantly higher in patients with cirrhosis or HCC than in controls –Levels differentiated between early HCC and cirrhosis Marrero J, et al. J Hepatol. 2005;43: *United Network for Organ Sharing modified TNM stages I and II. † P =.001 for early HCC vs cirrhosis in AFP measure.

clinicaloptions.com/hep Golgi Protein 73 as Serum Marker for HCC GP73 Appears to Be a Sensitive and Specific Marker for HCC Marrero J, et al. J Hepatol. 2005;43: Serum Marker, Median Relative Units (Range) AUROC* (95% CI)Sensitivity, %Specificity, % GP ( )6986 AFP 0.61 ( )3096 GP73 in early HCC 0.77 ( )6288 AFP in early HCC 0.62 ( )2597 AUROC, area under the receiver operating curve; CI, confidence interval. *P =.001 for GP73 vs AFP; P <.0001 for GP73 vs AFP.

clinicaloptions.com/hep Golgi Protein 73 as Serum Marker for HCC Key Conclusions  GP73 validated as serum indicator of HCC –Levels significantly higher in HCC patients than those with cirrhosis or healthy livers  GP73 serum levels may be superior to AFP levels for detecting HCC –Elevated in patients with normal AFP; more sensitive  GP73 serum levels elevated even in early HCC –Further validation needed to confirm the role of GP73 in the early detection of HCC Marrero J, et al. J Hepatol. 2005;43: